Recent Updates
Recently added Catalysts

orlistat experimental dose

Phase 1

Overweight | Small molecule | Metabolic |GSK plc|Last Updated: Jan 28, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment48

FDA Designations

No designations recorded

Clinical trial landscape

orlistat experimental dose · 1 trial · 1 indication

Phase 1 1
NCT01550926A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage FormsOverweight
COMPLETED48 Analytics
PHASE1COMPLETED
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
Overweight
NCT0155092648
Unlock trial analytics

Study Endpoints

Primary Endpoints

Fecal fat excretion
9 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER

Treatment Arms

ArmTypeDescription
Arm 1ACTIVE_COMPARATOR60 mg orlistat
Arm 2ACTIVE_COMPARATOR120 mg orlistat (2 X 60 mg capsules)
Arm 3EXPERIMENTALorlistat experimental formulation

Interventions

NameTypeDescription
120 mg orlistatDRUG2 X60 mg capsule
60 mg orlistatDRUG60 mg orlistat
orlistat experimental doseDRUGexperimental
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * age: 18-60 years * Body Mass Index: 25-33 Exclusion Criteria: * gastrointestinal disease * organ transplant * HIV, hepatitis B or C * food allergies * alcohol or other substance abuse * smoking

Countries:United Kingdom
Unlock Eligibility Criteria